MARKET

CGEM

CGEM

Cullinan Oncology Inc
NASDAQ
11.92
-0.46
-3.72%
After Hours: 11.92 0 0.00% 18:56 12/12 EST
OPEN
12.38
PREV CLOSE
12.38
HIGH
12.94
LOW
11.90
VOLUME
955.51K
TURNOVER
--
52 WEEK HIGH
13.60
52 WEEK LOW
5.68
MARKET CAP
704.19M
P/E (TTM)
-3.2390
1D
5D
1M
3M
1Y
5Y
1D
Cullinan Therapeutics price target raised to $33 from $22 at Clear Street
TipRanks · 4d ago
Cullinan Therapeutics Is Maintained at Outperform by Wedbush
Dow Jones · 5d ago
Wedbush Maintains Outperform on Cullinan Therapeutics, Raises Price Target to $34
Benzinga · 5d ago
Cullinan Therapeutics price target raised to $34 from $25 at Wedbush
TipRanks · 5d ago
Cullinan Management (CGEM) Gets a Buy from BTIG
TipRanks · 5d ago
CULLINAN THERAPEUTICS INC <CGEM.O>: WEDBUSH RAISES TARGET PRICE TO $34 FROM $25
Reuters · 5d ago
Promising Outlook for Cullinan Management: Buy Rating Backed by Strong Therapeutic Developments and Financial Position
TipRanks · 5d ago
Optimistic Buy Rating for Cullinan Management Driven by Promising CLN-049 Therapy Results
TipRanks · 5d ago
More
About CGEM
Cullinan Therapeutics, Inc. is a biopharmaceutical company. It has built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in autoimmune diseases and cancer. Its portfolio includes a range of modalities. Its pipeline includes CLN-978, CLN-619, Zipalertinib (CLN-081/TAS6417), CLN-049, and CLN-617. CLN-978 is a CD19xCD3 T cell engager being developed for autoimmune diseases. CLN-619 is a monoclonal antibody that stabilizes expression of MICA/B on the tumor cell surface to promote tumor cell lysis mediated by cytotoxic innate and adaptive immune cells. Zipalertinib (CLN-081/TAS6417) is an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor. CLN-049 is a FLT3xCD3 T cell engaging bispecific antibody. CLN-617 is a fusion protein combining two potent antitumor cytokines, interleukin-2 and interleukin-12 with tumor retention domains for the treatment of solid tumors.

Webull offers Cullinan Therapeutics Inc stock information, including NASDAQ: CGEM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CGEM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CGEM stock methods without spending real money on the virtual paper trading platform.